Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen cEO Annual Total Compensation ($) ($)
DEF 14A Proxy Statement — CEO Pay Ratio Disclosure
Latest, FY2025
24,693,120
Period ended Dec 31, 2025
Change on a year earlier
+1.1%
24,428,495 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO Annual Total Compensation ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24,693,120 | +1.1% | Proxy Statement (DEF 14A) (d13946ddef14a.htm, filed 2026-04-07) ↗ |
| FY2024 | Dec 31, 2024 | 24,428,495 | +7.9% | Proxy Statement (DEF 14A) (amgn-20250408.htm, filed 2025-04-09) ↗ |
| FY2023 | Dec 31, 2023 | 22,643,650 | +5.8% | Proxy Statement (DEF 14A) (d445034ddef14a.htm, filed 2024-04-17) ↗ |
| FY2022 | Dec 31, 2022 | 21,399,733 | -1.5% | Proxy Statement (DEF 14A) (d371686ddef14a.htm, filed 2023-04-06) ↗ |
| FY2021 | Dec 31, 2021 | 21,721,154 | +7.9% | Proxy Statement (DEF 14A) (d234450ddef14a.htm, filed 2022-04-05) ↗ |
| FY2020 | Dec 31, 2020 | 20,131,408 | +2.6% | Proxy Statement (DEF 14A) (d107745ddef14a.htm, filed 2021-04-06) ↗ |
| FY2019 | Dec 31, 2019 | 19,612,793 | – | Proxy Statement (DEF 14A) (d846287ddef14a.htm, filed 2020-04-07) ↗ |
Cite this data
StockData. (2026). Amgen CEO Annual Total Compensation ($) ($), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/proxy_ceo_comp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.